These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2904366)

  • 1. The role of neurotransmitters and opioids in polycystic ovarian syndrome.
    Lobo RA
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):667-83. PubMed ID: 2904366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovarian disease: animal models.
    Mahajan DK
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):705-32. PubMed ID: 2973982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamic-pituitary dysfunction in polycystic ovarian disease.
    Adashi EY
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):649-66. PubMed ID: 3143565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovarian disease as a neuroendocrine disorder of the female reproductive axis.
    Hall JE
    Endocrinol Metab Clin North Am; 1993 Mar; 22(1):75-92. PubMed ID: 8095452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromodulators and transmitters in respiratory control.
    Moss IR; Denavit-Saubié M; Eldridge FL; Gillis RA; Herkenham M; Lahiri S
    Fed Proc; 1986 Jun; 45(7):2133-47. PubMed ID: 2423376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the endogenous opioid system in polycystic ovary syndrome.
    Eyvazzadeh AD; Pennington KP; Pop-Busui R; Sowers M; Zubieta JK; Smith YR
    Fertil Steril; 2009 Jul; 92(1):1-12. PubMed ID: 19560572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical manifestations of polycystic ovarian disease.
    Young RL; Goldzieher JW
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):621-35. PubMed ID: 2973981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the etiopathogenesis of migraine: a possible link between the amines and endorphin hypotheses.
    Agnoli A; Denaro A; Ceci E; Falaschi P
    Adv Neurol; 1982; 33():99-106. PubMed ID: 6119897
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of ovulation in the patient with polycystic ovarian disease.
    Blankstein J; Quigley MM
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):733-49. PubMed ID: 3143566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of acupuncture on central neurotransmitters].
    Xia Y; Cao XD
    Zhen Ci Yan Jiu; 1985; 10(2):81-91. PubMed ID: 2868813
    [No Abstract]   [Full Text] [Related]  

  • 11. Polycystic ovarian disease.
    Raj SG; Talbert LM
    Obstet Gynecol Annu; 1984; 13():261-73. PubMed ID: 6232474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovary syndrome in adolescence.
    Blank SK; Helm KD; McCartney CR; Marshall JC
    Ann N Y Acad Sci; 2008; 1135():76-84. PubMed ID: 18574211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology.
    Balen A
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):685-706. PubMed ID: 15380141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain neurotransmitters regulating TRH producing neurons.
    Annunziato L; Di Renzo G; Quattrone A; Schettini G; Preziosi P
    Pharmacol Res Commun; 1981 Jan; 13(1):1-10. PubMed ID: 6111810
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome.
    van der Spuy ZM; Dyer SJ
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):755-71. PubMed ID: 15380145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
    Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
    Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endogenous opioid system in Gilles de la Tourette syndrome.
    Gillman MA; Sandyk R
    Med Hypotheses; 1986 Apr; 19(4):371-8. PubMed ID: 2872580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reproductive phenotype in polycystic ovary syndrome.
    Chang RJ
    Nat Clin Pract Endocrinol Metab; 2007 Oct; 3(10):688-95. PubMed ID: 17893687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease.
    Fulghesu AM; Lanzone A; Cucinelli F; Caruso A; Mancuso S
    Obstet Gynecol; 1993 Aug; 82(2):191-7. PubMed ID: 8336863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.